Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Stock Information for BriaCell Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BriaCell Therapeutics Corp.

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)
BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT(TM)
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)
BriaCell Therapeutics Announces Closing of Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.